NR293 PHARMACOLOGY FINAL EXAM
PART 2 STUDY GUIDE 2025
RAPID ACTING INSULIN - -onset: 15 minutes
peak: 30-90 minutes
insulin lispro (Humalog)
insulin aspart (NovoLog)
insulin glulisine (Apidra)
SHORT ACTING INSULIN - -*onset: 30-60 minutes
peak: 2-4 hours*
regular insulin (Humulin R)
regular insulin (Novolin R)
INTERMEDIATE ACTING INSULIN - -*onset: 1-3 hours*
*peak: 8 hours*
NPH insulin (Humulin N)
NPH insulin (Novolin N)
LONG-ACTING INSULIN - -*onset: 1-2 hours*
*no peak*
*duration: 18-24 hours*
insulin glargine (Lantus)
insulin detemir (Levemir)
PRE-MIXED INSULIN - -*onset = 30-60 minutes*
*peak: varies*
NR293
,NR293
70% NPH/30% Reg
(Humulin 70/30)
70% NPH/30% Reg
(Novolin 70/30)
50% NPH/50% Reg
(Humulin 50/50)
REGULAR INSULIN - -the only insulin that can be administered via IV route
used to treat diabetic ketoacidosis or diabetic coma
HYPOGLYCEMIA - -occurs when blood glucose is less than 70 mg/dL
HYPOGLYCEMIA - SIGNS & SYMPTOMS - -*Early Signs*
confusion
irritability
tremor
sweating
*Late Signs*
hypothermia
seizures
BLOOD SUGAR MNEMONIC - -HOT AND DRY = SUGAR HIGH
COLD AND CLAMMY = GIVE THEM CANDY
INSULIN - INDICATIONS - -used for glycemic control of diabetes mellitus (type 1, type
2, gestational)
INSULIN THERAPY FOR TYPE 2 DIABETES MELLITUS - INDICATIONS - -when oral
antidiabetic medications, diet, and exercise are
unable to control blood glucose levels.
severe renal or liver disease is present.
painful neuropathy is present.
undergoing surgery or diagnostic tests.
experiencing severe stress such as infection
and trauma.
NR293
,NR293
undergoing emergency treatment of diabetes ketoacidosis (DKA) and hyperosmolar
hyperglycemic
nonketotic syndrome
requiring treatment of hyperkalemia.
WHEN MIXING INSULINS - -*clear before cloudy*
1.) inject air into the cloudy vial
2.) inject air into the clear vial
3.) withdraw clear insulin
4.) withdraw cloudy insulin
ADA GLYCEMIC GOAL - -hemoglobin A1C level of less than 7%
ADA FASTING BLOOD GLUCOSE GOAL - -80- 130 mg/dL
SULFONYLUREAS - -second generation oral antidiabetic drugs
glipizide (Glucotrol)
glyburide (Diabeta)
glimepiride (Amaryl)
SULFONYLUREAS - MECHANISM OF ACTION - -bind to specific receptors on beta
cells in the pancreas to stimulate the release of insulin
decrease secretion of glucagon
SULFONYLUREAS - INDICATIONS - -for patients who still have functioning beta cells
in the pancreas
best for early stages of type 2 diabetes
SULFONYLUREAS - CONTRAINDICATIONS - -hypoglycemia
conditions that predispose to hypoglycemia
potential allergy to sulfonamide antibiotics
SULFONYLUREAS - ADVERSE EFFECTS - -hypoglycemia
NR293
, NR293
weight gain
skin rash
nausea
epigastric fullness
heartburn
CORTICOSTEROIDS - -can cause an increase in blood glucose levels
METFORMIN (GLUCOPHAGE) - INDICATIONS - -first-line oral drug for the treatment
of type 2 diabetes
also treats polycystic ovary syndrome (PCOS) as an off-label use
METFORMIN (GLUCOPHAGE) - MECHANISM OF ACTION - -*decreases insulin
resistance*
decreases glucose production by the liver
decreases glucose absorption from the GI tract
METFORMIN (GLUCOPHAGE) - CONTRAINDICATIONS - -patients with renal
disease/renal dysfunction
*serum creatinine levels*
> 1.5 mg/dL (males)
> 1.4 mg/dL (females)
alcoholism
metabolic acidosis
hepatic disease
heart failure
conditions that predispose to tissue hypoxia and increase the risk for lactic acidosis
METFORMIN (GLUCOPHAGE) - INTERACTIONS - -avoid alcohol when taking this
medication due to an increased risk for hypoglycermia
METFORMIN (GLUCOPHAGE) - ADVERSE EFFECTS - -abdominal bloating
NR293